Daicel (4202) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
17 Jun, 2026Executive summary
Net sales for Q1 FY2026/3 were ¥139.3bn, down 4.3% year-over-year, mainly due to foreign exchange fluctuations, lower sales in Materials and Engineering Plastics, and a slowing global recovery.
Operating income fell 25.3% year-over-year to ¥13.0bn, impacted by inventory carryover, increased depreciation, and regional uncertainties, despite productivity gains in Safety.
Income attributable to owners of parent dropped 40.6% year-over-year to ¥9.6bn, as prior year included a gain from sale of shares in affiliates.
Comprehensive income declined 67.2% to ¥11.13bn compared to the same quarter last year.
Financial highlights
EBITDA for 1Q was ¥22.8bn, down 15.3% year-over-year.
Ordinary income decreased 32.1% year-over-year to ¥12.3bn.
Gross profit decreased to ¥39.96bn from ¥43.53bn year-over-year.
EPS for the quarter was ¥36.29, compared to ¥58.70 in the prior year.
Total assets increased to ¥839.85bn as of June 30, 2025, up from ¥813.83bn at March 31, 2025.
Outlook and guidance
1Q net sales were in line with the first half forecast; operating income exceeded expectations due to cost reductions and deferred expenses.
2Q operating income is expected to decline due to lower automobile production and recognition of deferred expenses.
Full-year FY2026 net sales forecast at ¥600bn, with operating income projected at ¥54bn and net income at ¥54bn.
Operating profit projected at ¥54bn (up 9.1%), ordinary profit at ¥56bn (up 10.1%), and EPS forecast for the year is ¥203.68.
US tariffs are impacting Safety and Engineering Plastics, with price increases planned after 3Q.
Latest events from Daicel
- Strong 1H growth driven by plastics and Smart segment, but full-year net income guidance cut.4202
Q2 202517 Jun 2026 - Sales and profits fell on FX and global headwinds, but cost controls lifted select segment margins.4202
Q2 202617 Jun 2026 - Operating profit nearly doubled on strong demand and favorable exchange rates.4202
Q1 202517 Jun 2026 - Sales rose 5.1%, but profits declined; FY2026 outlook: higher sales, lower profits, stable dividends.4202
Q4 202517 Jun 2026 - Net sales up 4.4% year-over-year, but profit margins declined amid mixed segment results.4202
Q3 202517 Jun 2026 - Profits fell on lower sales, but healthcare and safety segments showed strong growth.4202
Q3 202617 Jun 2026 - Profits fell on impairment losses, but FY2027 net income is forecast to rebound strongly.4202
Q4 202617 Jun 2026